Avanos Medical, Inc.
Avanos Medical, Inc. (AVNS) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Avanos Medical, Inc. (AVNS), featuring income statements, balance sheets, and cash flow data.
Avanos Medical, Inc. (AVNS) Income Statement & Financial Overview
Explore comprehensive income reports for Avanos Medical, Inc. AVNS, broken down by year and quarter.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $175.00M | $167.50M | $179.60M | $170.40M |
| Cost of Revenue | $82.90M | $77.70M | $81.60M | $77.50M |
| Gross Profit | $92.10M | $89.80M | $98.00M | $92.90M |
| Gross Profit Ratio | $0.53 | $0.54 | $0.55 | $0.55 |
| R&D Expenses | $5.80M | $5.40M | $5.70M | $7.20M |
| SG&A Expenses | $75.70M | $75.70M | $79.70M | $74.30M |
| Operating Expenses | $81.50M | $79.50M | $516.50M | $80.90M |
| Total Costs & Expenses | $164.40M | $157.20M | $598.10M | $153.70M |
| Interest Income | $600000.00 | $1.50M | $800000.00 | $700000.00 |
| Interest Expense | -$6.20M | $2.10M | $2.80M | $3.20M |
| Depreciation & Amortization | $10.00M | $9.60M | $11.10M | $11.70M |
| EBITDA | -$80.10M | $21.40M | -$406.60M | $24.40M |
| EBITDA Ratio | -$0.46 | $0.13 | -$2.26 | $0.14 |
| Operating Income | -$74.50M | $10.30M | -$418.50M | $12.00M |
| Operating Income Ratio | -$0.43 | $0.06 | -$2.33 | $0.07 |
| Other Income/Expenses (Net) | -$1.40M | -$600000.00 | -$2.00M | -$2.50M |
| Income Before Tax | -$75.90M | $9.70M | -$420.50M | $9.50M |
| Income Before Tax Ratio | -$0.43 | $0.06 | -$2.34 | $0.06 |
| Income Tax Expense | -$7.10M | $3.10M | -$23.50M | $3.60M |
| Net Income | -$76.80M | $6.60M | -$397.30M | $4.30M |
| Net Income Ratio | -$0.44 | $0.04 | -$2.21 | $0.03 |
| EPS | $46.06 | $0.14 | -$8.64 | $0.09 |
| Diluted EPS | $46.06 | $0.14 | -$8.64 | $0.09 |
| Weighted Avg Shares Outstanding | $0.00 | $46.10M | $46.00M | $46.00M |
| Weighted Avg Shares Outstanding (Diluted) | $0.00 | $46.80M | $46.00M | $46.60M |
Financial performance has remained strong, with revenue growing from $170.40M in Q3 2024 to $175.00M in Q2 2025. Gross profit continued to perform well, with margins at 53% in the latest quarter. Operating income reached -$74.50M in Q2 2025, holding a steady -43% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$80.10M. Net income dropped to -$76.80M, keeping EPS at $46.06. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan